In addition, MAFG expression also negatively correlated with the survival of patients with liver hepatocellular carcinoma (n = 374) (Fig. S8B), uterine corpus endometrial carcinoma (n = 552) (Fig. S8C), lung squamous cell carcinoma (n = 502) (Fig. S8D), bladder urothelial carcinoma (n = 414) (Fig. S8E), and esophageal carcinoma (n = 162) (Fig. S8F). Here, MAFG is linked to bladder transitional cell carcinoma.